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Mutated methylenetetrahydrofolate 
reductase as a risk factor for spina bifida
Nathaüe M J van der Put, Régine P M Steegers-Theunissen, 
Phyllis Frosst, Frans J M Trijbels, Tom K A B  Eskes, 
Lambert P van den Heuvel, Edwin C M Mariman,
Martin den Heyer, Rima Rozen, Henk J Blom
Periconceptional folate supplementation reduces the risk 
of neural-tube defects. We studied the frequency of the 
677C-TF mutation in the 5,10-methylenetetrahydrofolate 
reductase (MTHFR) gene in 55 patients with spina bifida 
and parents of such patients (70 mothers, 60 fathers). 5% 
of 207 controls were homozygous for the 677CMT 
mutation compared with 16% of mothers, 10% of fathers, 
and 13% of patients. The mutation was associated with 
decreased MTHFR activity, low plasma folate, and high 
plasma homocysteine and red-cell folate concentrations. 
The 677C->T mutation should be regarded as a genetic 
risk factor for spina bifida.
Lancet 1995; 3 4 6 :1070-71
Periconceptional folate supplementation reduces the 
occurrence and recurrence risk of neural-tube defects 
(NTD), but the protective mechanism remains 
unknown.1,2 Mothers of NTD offspring do not have 
deficient folate" concentrations, but the values are at the 
lower end of the control range. We3 and others4 have 
shown higher than normal plasma homocysteine 
concentrations in mothers of NTD offspring. Since 
plasma homocysteine is a sensitive marker of folate status, 
we suggested that folate metabolism was abnormal in 
these mothers.3
Reduced activity of 5,10-methylenetetrahydrofolate 
reductase (MTHFR) is associated with high plasma 
homocysteine concentrations.5,(5 We have isolated the 
human MTHFR cDNA and localised the gene to 
chromosome lp36,3.7 We identified a 677C—>T mutation 
in the MTHFR gene, resulting in decreased activity,
increased thermolability of the enzyme, and raised plasma
t
homocysteine concentrations.8 This mutation was studied 
as a risk factor for spina bifida.
Patients with spina bifida and their parents were recruited in 
1993 in collaboration with a Dutch society for patients with 
central nervous system defects (BOSK). The protocol was 
approved by the local ethics committee and written informed 
consent was obtained. The study group consisted of 70 mothers 
(mean age 45‘7 [SD 11*7] years), 60 fathers (47*6 [11’6] years), 
and 55 children and adults with spina bifida (23*3 [11*6] years). 
Children younger than 3 years were excluded.
A control group of 207 unrelated Dutch subjects (53*0 [12*1] 
years) was recruited in 1993 from a general practice in The 
Hague.0 Subjects with spina bifida themselves or in an offspring 
were excluded.
The prevalence of the 677C-»T mutation was investigated by 
PCR of genomic DNA and restriction enzyme digestion with 
Hinfl* Specific and residual (after heat inactivation for 5 min at 
46°C) M TH FR activities were measured by a radiochemical 
assay in lymphocytes isolated from heparinised blood.6 
Homocysteine concentrations were measured in EDTA plasma.10 
Folate and vitamin B 12 concentrations in heparinised plasma,
Genotype
+ / " +/+
% of group (number of subjects)
Controls (n=207) 54(111) 42 (86) 5(10)
Mothers (n=70) 46 (32) 39(27) 16(11)
Fathers (n=60) 48 (29) 42(25) 10(6)
Patients (n=55) 40 (22) 47 (26) 13(7)
Mean (SD) metabolite concentration
Homocysteine (pmol/L) 13-4 ( 3*4) 13-2 (3*1) 174 (11-5)*
Vitamin B12 (pmol/L) 246(130) 271(121) 233(94)
Red-cell folate (nmol/L) 541(188) 517 (182) 643(186) +
Plasma folate (nmol/L) 12-8(6-5) 12-8 (6-7) 9-5 (3-1)*
♦Significantly different from - / -  and + / -  groups by AN0VA; p (two-tailed) <0-02.
Table: Prevalence of 677C-VT mutation (+) and biochemical 
measurements
and red-cell folate were measured by Dualcount Solid Phase Boil 
Radioassay (Diagnostic Products, Los Angeles, CA, USA).
Odds ratios (with 95% Cl) were calculated to estimate the 
relative risk of the homozygous mutation.
The odds ratios for the homozygous mutation were 3-7 
(95% Cl 1 *5-9*1) for the mothers, 2-2 (0-8-6*3) for the 
fathers, and 2*9 (1’0-7-9) for the patients versus the 
controls (table).
The presence of the 677C—>T mutation was strongly
i
related to M THFR activity and thermoiability (figure). 
The 677C->T mutation was associated with decreased 
activity in homozygous individuals and even in 
heterozygous individuals (ANOVA, p<0‘005 between all 
three genotypes). M THFR activities were independent of 
sex and age (data not shown).
The 677C—>T mutation was associated with increased 
plasma homocysteine and red-cell folate concentrations 
and decreased plasma folate in comparison witii the 
heterozygotes and the wild-type (table). Vitamin B12 
concentrations were similar in all three groups.
The 677C—»T mutation is the first identified genetic 
risk factor for spina bifida. Not only for mothers but also 
for patients a homozygous +/+ genotype is a risk factor 
for spina bifida. The odds ratios are only modestly raised 
but the risk factor is important because the frequency of 
homozygous mutants is 5% in the general population.
The product of MTHFR, 5-methyltetrahydrofolate, is 
the predominant form of folate in plasma, whereas other
H1
folate derivatives such as the enzyme substrate, 
methylenetetrahydrofolate, are found mainly within cells. 
The effect of -decreased M TH FR activity on folate 
metabolism is reflected by raised red-cell and decreased 
plasma folate concentrations in individuals homozygous 
for the mutation.
The body can only convert 5-methyltetrahydrofolate by 
methyl-group donation to homocysteine, resulting in 
formation of tetrahydrofolate and methionine. Raised 
plasma homocysteine can be explained by reduced 
availability of 5-methyltetrahydrofolate in homozygous
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Figure: Specific versus residual MTHFR activity of controls and
families with spina bifida offspring
Specific-activity=nmol CH20 per mg protein per hour.
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mutants. Our findings support the hypothesis of defective 
folate metabolism in at least a subset of mothers with 
N FD offspring.M The genotypes of the mother and of die 
father contribute to the risk of having a child with spina 
bifida. Since folate administration may overcome the 
effects of reduced M TH FR  activity, our findings provide 
a mechanism for the protective role of folate in the 
aetiology of spina bifida in individuals homozygous for the 
077C—:>T mutation.
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Role of thrombin in pulmonary fibrosis
Norma A Herntindez-Rodriguez, Alison D Cambrey, 
Nicholas K Harrison, Rachel C Chambers,
Andrew J Gray, Anne M Southcott, Roland M duBois, 
Carol M Black, Michael F Scully, Robin J McAnulty, 
Geoffrey J Laurent
(BALF) from patients with systemic sclerosis* healthy 
controls, and two other groups of patients with 
pulmonary fibrosis—cryptogenic fibrosing alveolitis and 
sarcoidosis* The contribution of thrombin to BALF-
Pulmonary fibrosis commonly develops in systemic 
sclerosis. We assessed the role of thrombin in promoting 
fibroblast proliferation in the lungs in this disorder. 
Bronchoalveolar lavage fluid (BALF) thrombin 
concentrations were higher in ten patients with systemic 
sclerosis than in 12 healthy controls (14*6 vs 3*6 nmol/Lf 
p<0-02), but values in patients with cryptogenic fibrosing 
alveolitis (n~10) or sarcoidosis (n=10) were not increased. 
BALF from all patients induced fibroblast proliferation. This 
proliferation was attenuated by thrombin inhibitors for 
BALF from systemic sclerosis patients only. We suggest 
thrombin contributes to lung fibroblast proliferation in this 
disorder.
Lancet 1995; 3 4 6 :1 0 7 1 -7 3
Systemic sclerosis is a multisystem disease; a major 
characteristic is the uncontrolled deposition of 
extracellular matrix components in the skin and internal 
organs. The lungs are involved in most patients, and 
pulmonary fibrosis is a common cause of deatii.1 One 
hypothesis for the pathogenesis is that after endothelial 
injury, bloodborne mediators or their precursors move 
from the circulation into adjacent tissues and activate 
fibroblasts to proliferate or produce excess extracellular 
matrix.--‘ One candidate mediator is thrombin, a key 
enzyme in the coagulation cascade, which is also a potent 
mitogen and ehemoattractant for fibroblasts/1’'5 
To investigate the role of thrombin in promoting 
fibroblast proliferation in the lungs, we measured 
thrombin concentrations in bronchoalveolar lavage fluid
induced fibroblast proliferation was assessed with specific 
inhibitors of thrombin activity, hirudin, and PPACK 
(D -p h en y la lan in e -p ro lin e -a rg in in e -m e th y lch lo r id e ) ,  
which block the catalytic site,
We studied ten patients with systemic sclerosis (with no clinical 
evidence of pulm onary hypertension), ten with cryptogenic 
fibrosing alveolitis, ten with sarcoidosis, and 12 healthy 
volunteers, BALF (from bronchoalveolar lavage) was centrifuged, 
and the cell-free supernatant concentrated ten-fold by 
ultrafiltration. Throm bin  was m easured spectrophotometrically .'1
Cell proliferation was assessed in hum an fetal and adult lung 
fibroblasts by a rapid spectrophotom etric  assay.7 Cells were 
seeded (6X 101 per well) in Dulbecco's modified Eagle's m edium  
plus 0*4% newborn calf serum. After 24 h  incubation at 37°C in 
humidified air with 10% carbon dioxide, the m edium  from each 
well was replaced with fresh m edium  plus BA LF at final dilutions 
between 1 in 16 and 1 in 128 or purified hum an  u-throm bin  at 
concentrations up to 1 nmol/L. Fibroblasts exposed to medium 
plus newborn calf serum alone were used as controls. O ptim um  
concentrations of thrombin inhibitors (hirudin 6 nmol/L, 
PPACK 5 pmol/L) were preincubated with BA LF or thrombin 
for 20 min before addition to cells. Changes in cell num ber were 
assessed 48 h later. Results were expressed as percentage change 
in mean absorbance compared with controls containing medium 
only. Im portan t results were confirmed by direct cell counting.
Group data are expressed as m edian and range. Initial 
statistical analysis was by non-para  metric one-way analysis of 
variance (Kruskal-Wallis test). I f  this test suggested that the 
groups were not derived from populations with the same median, 
two-sample M ann-W hitney tests (unless stated otherwise) were 
used to identify differences. T h e  effects o f  thrombin and 
inhibitors on fibroblast proliferation were com pared by / test,
Thrombin concentrations in BALF were higher than 
the highest control value in all die systemic sclerosis 
patients (figure 1); this median value was four-fold greater 
than that in controls (p<0-02). When expressed with 
respect to albumin the difference was two-fold (13*1
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